<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02480894</url>
  </required_header>
  <id_info>
    <org_study_id>206278</org_study_id>
    <secondary_id>AI438-052</secondary_id>
    <nct_id>NCT02480894</nct_id>
  </id_info>
  <brief_title>A Open-label, Drug-Drug Interaction With Maraviroc (DDI)</brief_title>
  <official_title>A Phase 1, Open-label, Drug-drug Interaction Study Between BMS-663068 and Maraviroc in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ViiV Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, open-label, single sequence, two-way interaction study in healthy male and
      female subjects. For the effect of maraviroc on the pharmacokinetics (PK) of BMS-626529 (the
      active moiety of BMS-663068), there is no formal hypothesis to be statistically tested. The
      purpose of this assessment is to estimate the effect of maraviroc on the PK of BMS-626529
      when coadministered in healthy subjects. For the effect of BMS-663068 on the PK of maraviroc,
      the hypothesis to be statistically tested is that BMS-663068 will not have a clinically
      significant effect on the PK of maraviroc when coadministered in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 7, 2015</start_date>
  <completion_date type="Actual">September 21, 2015</completion_date>
  <primary_completion_date type="Actual">September 21, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BMS-626529 Pharmacokinetics: maximum observed plasma concentration (Cmax)</measure>
    <time_frame>predose and up to 12 hours post dose on Days 4, 16, 17, and 18</time_frame>
    <description>PK parameters for BMS-626529 in the absence or presence of multiple doses of maraviroc include:
- Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>BMS-626529 Pharmacokinetics: area under the plasma concentration-time curve (AUC) in a single dosing interval AUC(TAU)</measure>
    <time_frame>predose and up to 12 hours post dose on Days 4, 16, 17, and 18</time_frame>
    <description>PK parameters for BMS-626529 in the absence or presence of multiple doses of maraviroc include:
- AUC(TAU)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maraviroc Pharmacokinetics: Cmax</measure>
    <time_frame>predose and up to 12 hours post dose on Days 9, 10, 11, 16, 17, and 18</time_frame>
    <description>PK parameters for maraviroc in the absence or presence of BMS-663068 include:
- Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maraviroc Pharmacokinetics: AUC(TAU)</measure>
    <time_frame>predose and up to 12 hours post dose on Days 9, 10, 11, 16, 17, and 18</time_frame>
    <description>PK parameters for maraviroc in the absence or presence of BMS-663068 include:
- AUC(TAU)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other PK Parameters for BMS-626529: Time of maximum observed plasma concentration (Tmax)</measure>
    <time_frame>predose and up to 12 hours post dose on Days 4, 16, 17, and 18</time_frame>
    <description>PK parameters for BMS-626529 include:
- Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other PK Parameters for BMS-626529: plasma concentration observed at 12 hours post-dose (C12)</measure>
    <time_frame>predose and up to 12 hours post dose on Days 4, 16, 17, and 18</time_frame>
    <description>PK parameters for BMS-626529 include:
- C12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other PK Parameters for BMS-626529: trough observed plasma concentration (Ctrough) (predose)</measure>
    <time_frame>predose and up to 12 hours post dose on Days 4, 16, 17, and 18</time_frame>
    <description>PK parameters for BMS-626529 include:
- Ctrough (predose)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other PK Parameters for maraviroc: Tmax</measure>
    <time_frame>predose and up to 12 hours post dose on Days 9, 10, 11, 16, 17, and 18</time_frame>
    <description>PK Parameters for maraviroc include:
-Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other PK Parameters for maraviroc: C12</measure>
    <time_frame>predose and up to 12 hours post dose on Days 9, 10, 11, 16, 17, and 18</time_frame>
    <description>PK Parameters for maraviroc include:
C12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other PK Parameters for maraviroc: Ctrough</measure>
    <time_frame>predose and up to 12 hours post dose on Days 9, 10, 11, 16, 17, and 18</time_frame>
    <description>PK Parameters for maraviroc include:
- Ctrough</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Safety as Measured by Adverse Events</measure>
    <time_frame>Day 1 to Day 26</time_frame>
    <description>Adverse event monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Safety as Measured by Vital Signs</measure>
    <time_frame>Day 1 to Day 26</time_frame>
    <description>Vital sign measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Safety as Measured by Electrocardiograms (ECGs)</measure>
    <time_frame>Day 1 to Day 26</time_frame>
    <description>12-lead ECGs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Safety as Measured by Physical Examination</measure>
    <time_frame>Day 1 to Day 26</time_frame>
    <description>Physical examinations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Safety as Measured by Clinical Laboratory Evaluations</measure>
    <time_frame>Day 1 to Day 26</time_frame>
    <description>Clinical chemistry, hematology, urinalysis</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Infection, Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>Sequential Dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment A: BMS-663068 orally twice daily (BID) on Days 1 through 4 Treatment B: Maraviroc BID on Days 7 through 11 Treatment C: BMS-663068 BID plus maraviroc BID on Days 12 through 18</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-663068</intervention_name>
    <description>BMS-663068</description>
    <arm_group_label>Sequential Dosing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maraviroc</intervention_name>
    <description>Maraviroc</description>
    <arm_group_label>Sequential Dosing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female nonsmoking subjects ages 18 to 50 years, inclusive with a body
             mass index of 18.0 to 32.0 kg/m2, inclusive

          -  Women of childbearing potential must agree to follow instructions for methods of
             contraception for a total of 34 days post-treatment completion

        Exclusion Criteria:

          -  Any condition possibly affecting drug absorption

          -  Pre-existing liver dysfunction

          -  Any significant acute or chronic medical illness

          -  Orthostatic intolerance

          -  Other protocol specified exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>ViiV Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2015</study_first_submitted>
  <study_first_submitted_qc>June 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2015</study_first_posted>
  <last_update_submitted>September 20, 2017</last_update_submitted>
  <last_update_submitted_qc>September 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maraviroc</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

